Concord Biotech reported its consolidated financial results for the quarter ending March 2026, revealing a significant decline in key metrics. Net sales amounted to ₹326.08 crore, reflecting a 24.15% decrease compared to ₹429.88 crore in the same quarter of the previous year. The company's net profit also saw a substantial drop of 36.75%, falling to ₹88.79 crore from ₹140.39 crore year-on-year. EBITDA decreased by 33%, coming in at ₹133.88 crore, down from ₹199.81 crore in March 2025. The earnings per share (EPS) for the quarter was reported at ₹8.46, a decline from ₹13.42 in the previous year. The company’s shares were valued at ₹1,166.20 as of June 1, 2026. These results indicate a challenging financial period for Concord Biotech, prompting scrutiny from investors and analysts regarding the factors contributing to these declines.